نتایج جستجو برای: cd30 antigen

تعداد نتایج: 201716  

Journal: :American journal of clinical pathology 2000
J C Cheville S Rao K A Iczkowski C M Lohse V S Pankratz

We studied cytokeratin (CK) expression immunohistochemically in 64 seminomas using a panel of commercially available antikeratin antibodies and tested for association of CK expression with patient age, tumor size, stage, and outcome. Seventeen embryonal carcinomas were compared with seminoma. CK7, CAM 5.2, AEI/AEIII, and wide-spectrum screening keratin (WSK) were positive in 41%, 30%, 36%, and ...

Journal: :Iranian journal of allergy, asthma, and immunology 2011
Mohammad Jafar Mahmoudi Mona Hedayat Nima Rezaei Ali-Akbar Saboor-Yaraghi Maryam Mahmoudi

The CD30 antigen seems to play a costimulatory role in maintaining the physiological balance between T-helper (Th)1/Th2 immune responses. In this study, plasma and in vitro soluble CD30 (sCD30) secretion was investigated in patients with coronary artery disease (CAD) as a plausible marker of dysregulated immune response.Twenty one patients with angiographically confirmed CAD and 31 healthy cont...

2017
Angela C. Zhou Laura M. Snell Michael E. Wortzman Tania H. Watts

CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin's disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans. A limited number of studies have assessed the physiological role of CD30/CD30 ligand interactions in control of infection in mice. Here, we assess the role of CD30 in T-cell immunity to ac...

Journal: :The Journal of biological chemistry 2006
May S Kung Sutherland Russell J Sanderson Kristine A Gordon Jamie Andreyka Charles G Cerveny Changpu Yu Timothy S Lewis Damon L Meyer Roger F Zabinski Svetlana O Doronina Peter D Senter Che-Leung Law Alan F Wahl

The chimeric anti-CD30 monoclonal antibody cAC10, linked to the antimitotic agents monomethyl auristatin E (MMAE) or F (MMAF), produces potent and highly CD30-selective anti-tumor activity in vitro and in vivo. These drugs are appended via a valine-citrulline (vc) dipeptide linkage designed for high stability in serum and conditional cleavage and putative release of fully active drugs by lysoso...

2018
Stefan Schönberger Cornelius van Beekum Barbara Götz Daniel Nettersheim Hubert Schorle Dominik T Schneider Anna Casati Rogerio B Craveiro Gabriele Calaminus Dagmar Dilloo

Prognosis in patients suffering from high-risk, refractory and relapsed germ cell tumours (GCT) often comprising of CD30-positive embryonal carcinoma (EC) components remains poor. Thus, novel treatment strategies are warranted. The antibody-drug conjugate (ADC) brentuximab vedotin delivers the potent antimitotic drug monomethyl auristatin E (MMAE) to CD30-expressing tumour cells. After CD30 bin...

Journal: :Blood 2013
Shimin Hu Zijun Y Xu-Monette Aarthi Balasubramanyam Ganiraju C Manyam Carlo Visco Alexander Tzankov Wei-min Liu Roberto N Miranda Li Zhang Santiago Montes-Moreno Karen Dybkær April Chiu Attilio Orazi Youli Zu Govind Bhagat Kristy L Richards Eric D Hsi William W L Choi J Han van Krieken Qin Huang Jooryung Huh Weiyun Ai Maurilio Ponzoni Andrés J M Ferreri Xiaoying Zhao Jane N Winter Mingzhi Zhang Ling Li Michael B Møller Miguel A Piris Yong Li Ronald S Go Lin Wu L Jeffrey Medeiros Ken H Young

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic fact...

2015
Xiaoxiao Hao Xiaolei Wei Fen Huang Yongqiang Wei Hong Zeng Linwei Xu Qinjun Zhou Ru Feng

The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to pres...

2018
Rong Wang Liang Li Shenghua Zhang Yi Li Xiaofei Wang Qingfang Miao Yongsu Zhen

CD30 is a 120-kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. Overexpression of CD30 has been reported in Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL). CD30-targeted treatment with antibody-drug conjugates (ADCs) can lead to promising clinical benefit. Lidamycin (LDM), consisting of an apoprotein LDP and an active enediyne ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید